drugset / Trial / NCT07630727
Study of AHB-171 in Chronic Hepatitis B Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)
Timeline
- Start
- 2026-06-24
- Primary completion
- 2029-03-31
- Completion
- 2029-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AHB-171 | Unknown | — | Subcutaneous |